ARCH Venture Partners XII, LLC bought $10.0M of Prime Medicine (PRME)

Executed Aug 1 2025, disclosed Aug 1 2025, the same day.

Value, as filed

$10.0M

3,030,300 sh × $3.30

Executed

Aug 1 2025

the trade date, as filed

Disclosed

Aug 1 2025

0 days after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

-7.7%

-7.7% from execution

Over the 21 trading sessions from the disclosed entry session (Aug 1 2025), the stock returned -7.7% (delay-adjusted); from the execution session (Aug 1 2025), -7.7%. Derived: entry at the session's open, exit at the close 20 sessions later.

The filer

AL ARCH Venture Partners XII, LLC 10% owner profile →

ARCH Venture Partners XII, LLC (10% owner) filed 2 Form 4 reports as a reporting entity in the trailing twelve months (2 purchases, 0 sales), most often in Neumora Therapeutics, Inc. (NMRA). Across 2 priced purchase filings, the average 21-session return was -14.8% from execution and -11.1% from disclosure (delay-adjusted; derived). The largest single filing was $19.8M of SPTX (1,100,000 sh × $18.00, as filed), executed May 4.

The name

PRME PRME PRME · 6 filings in 24 months ticker → Insider filings, newest first→ View the original filing at www.sec.gov→